Tuesday, May 26, 2020 2:45:27 PM
First, it is an antibody cocktail, but they have identified ONE antibody.
Second, a 50% probability of success on a product might apply going into human trials, but not yet.
Share price target of implies a near five-fold gain on expected successful development of antibody cocktail
Shares of Sorrento Therapeutics Inc. rallied Tuesday, after a Wall Street analyst suggested the biopharmaceutical company was a good bet to successfully develop an "antibody cocktail" that could shield people from the COVID-19 virus.
The stock(SRNE) rose 3.0% in active afternoon trading Tuesday. Trading volume was 52.0 million shares, which exceeded the full-day average of about 41.1 million shares.
The gain follows a hectic week of trading, that followed up the 158% blast off on massive volume of 507.6 million shares on May 15 after the company provided an upbeat assessment (http://www.marketwatch.com/story/sorrento- therapeutics-stock-soars-on-massive-volume-after-upbeat-report-on-covid-19-antibody-experiment-2020-05-15) of the results of a preclinical experiment of its COVID-19 virus antibody, STI-1499.
The San Diego -based company said that STI-1499 demonstrated complete inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a "very low antibody concentration." Sorrento reiterated that it aims to generate an "antibody cocktail" product (http://www.marketwatch.com/story/sorrentos-stock-jumps-on-antibody-plans-with-mount-sinai- health-system-2020-05-08) that could act as a "protective shield" against coronavirus infection.
Analyst Jason Kolbert at Dawson James Securities initiated coverage of Sorrento with a buy rating, which for Dawson James means the stock is expected to produce a total return of at least 20% over the next 12 to 18 months.
But Kolbert expects a lot more than that, as he set a stock price target of $24 .
He suggested the stock is a good bet for investors, as he assumes the company will successfully develop the "COVI- SHIELD" antibody cocktail that it aims to produce.
"We apply a probability of success of just 50%, but given the size of the indication, the valuation potential for COVID alone is large," Kolbert wrote in a note to clients.
His view also includes the company's assertion that it can produce up to 200,000 does a month, with management saying it believes it can produce tens of millions of doses in a short period.
The company has said it has determined that STI-1499 will likely be the first antibody in the COVI-SHIELD cocktail that it is developing, and could also be developed as a stand-alone therapy--COVI-GUARD-- given the high potency it has exhibited.
Sorrento has said it plans to request priority evaluation and accelerated review from regulators.
The stock has now run up 55% year to date, while the iShares Nasdaq Biotechnology exchange-traded fund(IBB) has gained 10.4% and the S&P 500 index has lost 6.8%.
- Tomi Kilgore ; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
05-26-20 1437ET
Copyright (c) 2020 Dow Jones & Company, Inc.
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM